Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

The role of interferon regulatory factor-1 and interferon regulatory factor-2 in IFN-gamma growth inhibition of human breast carcinoma cell lines.

Authors:
John H Yim Simon H Ro Jennifer K Lowney Susan J Wu Judith Connett Gerard M Doherty

J Interferon Cytokine Res 2003 Sep;23(9):501-11

Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.

Interferon (IFN) regulatory factor-1 (IRF-1) and IRF-2 play opposing roles in the regulation of many IFN-gamma-inducible genes. To investigate the signal transduction pathway in response to IFN-gamma in light of differences in growth effects, we selected four human breast carcinoma cell lines based on a spectrum of growth inhibition by IFN-gamma. MDA468 growth was markedly inhibited by IFN-gamma, and it showed substantial induction of IRF-1 mRNA but little IRF-2 induction. SKBR3 showed little growth inhibition and little induction of IRF-1 mRNA but significant induction of IRF-2 mRNA. HS578T and MDA436 growth inhibition and IRF-1/IRF-2 induction were intermediate. All four cell lines showed intact receptor at the cell surface and Stat1 translocation to the nucleus by immunostaining. By EMSA, there were marked differences in the induced ratio of IRF-1 and IRF-2 binding activity between the cell lines that correlated with growth inhibition. Finally, antisense oligonucleotides specific for IRF-1 attenuated IFN-gamma growth inhibition in MDA436 and MDA468, confirming the direct role of IRF-1 in IFN-gamma growth inhibition. Induction of IRF-1 causes growth inhibition in human breast cancer cell lines, and induction of IRF-2 can oppose this. The relative induction of IRF-1 to IRF-2 is a critical control point in IFN-gamma response.

Download full-text PDF

Source
http://dx.doi.org/10.1089/10799900360708623DOI Listing
September 2003

Publication Analysis

Top Keywords

growth inhibition
32
cell lines
20
induction irf-1
16
human breast
12
irf-1 irf-2
12
ifn-gamma growth
12
growth
10
inhibition induction
8
carcinoma cell
8
inhibition human
8
inhibition
8
irf-1
8
interferon regulatory
8
induction
8
regulatory factor-1
8
irf-1 mrna
8
induction irf-2
8
breast carcinoma
8
ifn-gamma
7
cell
6

Keyword Occurance

Similar Publications

Predictive macroscopic modeling of cell growth, metabolism and monoclonal antibody production: Case study of a CHO fed-batch production.

Authors:
Bassem Ben Yahia Laetitia Malphettes Elmar Heinzle

Metab Eng 2021 Apr 19. Epub 2021 Apr 19.

Biochemical Engineering Institute, Saarland University, Campus A1.5, D-66123 Saarbrücken (Germany). Electronic address:

We describe a systematic approach to establish predictive models of CHO cell growth, cell metabolism and monoclonal antibody (mAb) formation during biopharmaceutical production. The prediction is based on a combination of an empirical metabolic model connecting extracellular metabolic fluxes with cellular growth and product formation with mixed Monod-inhibition type kinetics that we generalized to every possible external metabolite. We describe the maximum specific growth rate as a function of the integral viable cell density (IVCD). Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Development of ciclesonide analogues that block SARS-CoV-2 RNA replication.

Authors:
Genichiro Tsuji Kenzo Yonemitsu Takahito Ito Yuta Yanase Masashi Uema Nobumichi Ohoka Takao Inoue Hiroshi Asakura Yosuke Demizu

Bioorg Med Chem Lett 2021 Apr 19:128052. Epub 2021 Apr 19.

Division of Organic Chemistry, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki, Kanagawa 210-9501, Japan; Graduate School of Medical Life Science, Yokohama City University, 1-7-29, Yokohama, Kanagawa 230-0045, Japan. Electronic address:

Ciclesonide is an inhaled corticosteroid used to treat asthma and is currently undergoing clinical trials for treatment of coronavirus disease 2019 (COVID-19). An active metabolite of ciclesonide, Cic2, was recently reported to repress severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genomic RNA replication. Herein, we designed and synthesized a few types of ciclesonide analogues. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.

Authors:
Adrián Vallejo Oihane Erice Rodrigo Entrialgo-Cadierno Iker Feliu Elizabeth Guruceaga Maria J Perugorria Paula Olaizola Alexandra Muggli Irati Macaya Michael O'Dell Borja Ruiz-Fernandez de Cordoba Sergio Ortiz-Espinosa Aram F Hezel Imanol Arozarena Fernando Lecanda Matias A Avila Maite G Fernández-Barrena Matthias Evert Mariano Ponz-Sarvise Diego F Calvisi Jesus M Banales Silve Vicent

J Hepatol 2021 Apr 14. Epub 2021 Apr 14.

University of Navarra, Centre for Applied Medical Research, Program in Solid Tumours, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC, Instituto de Salud Carlos III), Madrid, Spain; University of Navarra, Department of Pathology, Anatomy and Physiology, Pamplona, Spain. Electronic address:

Background And Aims: Cholangiocarcinoma (CCA) is a neoplasia of the biliary tract driven by genetic, epigenetic and transcriptional mechanisms. Here, we investigated the role of the transcription factor FOSL1, as well as its downstream transcriptional effectors, in the development and progression of CCA.

Methods: FOSL1 was investigated in human CCA clinical samples. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Remodeling of immunological biomarkers in patients with chronic hepatitis C treated with direct-acting antiviral therapy.

Authors:
Isabela Gomes Ribeiro Jordana Grazziela Alves Coelho-Dos-Reis Jordana Rodrigues Barbosa Fradico Ismael Artur da Costa-Rocha Luciana Diniz Silva Lucy Ana Dos Santos Fonseca Rhaissa Carvalho Said Stancioli Andréa Teixeira-Carvalho Olindo Assis Martins-Filho Rosângela Teixeira

Antiviral Res 2021 Apr 19:105073. Epub 2021 Apr 19.

Pós-graduação Em Ciências Aplicadas da Saúde Do Adulto, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Ambulatório de Hepatites Virais, Instituto Alfa de Gastroenterologia, Hospital Das Clínicas/ Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. Electronic address:

The HCV treatment with DAAs has offered a unique opportunity to analyze the changes in the immune system caused by the rapid inhibition of viral replication. We sought to analyze the kinetics profiles of serum biomarkers (LuminexTM) in fifty patients with chronic hepatitis C enrolled in a longitudinal investigation carried out before (baseline), during (W2-4 and W8-12 weeks) and post-treatment (W12-24 weeks) with sofosbuvir plus daclatasvir or simeprevir. The results demonstrated a clear biomarker overproduction in HCV patients at baseline. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.

Authors:
Ahmed A E Mourad N A Farouk El-Sherbiny H El-Sayed Ahmed R E Mahdy

Life Sci 2021 Apr 19:119531. Epub 2021 Apr 19.

Chemistry Department, Faculty of Science, Port-Said University, Port-Said, Egypt.

Aims: EGFR and VEGFR-2 have emerged as promising targets for cancer management as they play a crucial role in tumor growth, angiogenesis and metastasis. A novel series of 2-thioxoimidazolidin-4-one derivatives were synthesized and evaluated as apoptotic inducers and EGFR/VEGFR-2 dual inhibitors.

Main Methods: The cytotoxic activities of all synthesized compounds were tested against MCF-7, HepG2 and A549 cell lines. Read More

View Article and Full-Text PDF
April 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap